VESALIUS-CV:依洛尤单抗对无心肌梗死或卒中病史高危患者总体MACE的累积获益
VESALIUS-CV 试验纳入 12257 例无心肌梗死或卒中病史、LDL-C≥90 mg/dL 的高危患者,中位随访 4.6 年。预设分析显示,依洛尤单抗较安慰剂显著降低首次及后续 MACE 事件。每 1000 例患者 5 年内预计可预防 55 例 4 点 MACE 或 25 例 3 点 MACE 总事件。
要点
- 无 MI 或卒中病史的高危患者中,再发 MACE 占比高,4 点 MACE 后续事件比首次事件多 67%。
- 依洛尤单抗同时降低首次和后续 MACE,支持强化降 LDL-C 以预防复发事件。
- 获益在关键亚组中一致,包括不同他汀强度和是否有动脉粥样硬化。
核心结论
- 在高心血管风险且无心肌梗死或卒中病史的患者中,相当比例发生心血管事件者经历了 1 次以上事件。
- 加用依洛尤单抗可降低总 MACE 数量,支持强化降低 LDL-C 以预防首次及后续 MACE。
研究设计与样本
- VESALIUS-CV 为随机对照试验,纳入 12257 例有动脉粥样硬化或高危糖尿病、无心肌梗死或卒中病史、优化降脂治疗下 LDL-C≥90 mg/dL 的患者。
- 患者随机分配至依洛尤单抗组或安慰剂组,中位随访 4.6 年。
- 双主要终点为 4 点 MACE(冠心病死亡、心肌梗死、缺血性卒中或缺血驱动的动脉血运重建)和 3 点 MACE(不含血运重建)。
- 预设分析采用负二项回归模型分析首次及后续全部双主要终点事件。
主要发现
- 12257 例患者中发生 1654 例首次 4 点 MACE 和 1107 例后续事件(多出 67%),共 2761 例总事件。
- 发生 779 例首次 3 点 MACE 和 146 例后续事件(多出 19%),共 925 例总事件。
- 依洛尤单抗使首次 4 点 MACE 风险降低 19%(HR:0.81;95% CI:0.73-0.89;P<0.0001),后续事件降低 25%(IRR:0.75;95% CI:0.61-0.91),总事件降低 20%(IRR:0.80;95% CI:0.71-0.90;P=0.0002)。
- 依洛尤单抗使首次 3 点 MACE 风险降低 25%(HR:0.75;95% CI:0.65-0.86;P<0.0001),后续事件降低 37%(IRR:0.63;95% CI:0.42-0.94),总事件降低 27%(IRR:0.73;95% CI:0.63-0.86;P=0.0001)。
- 结果在关键亚组中一致,包括按他汀强度和是否有动脉粥样硬化分层。
关键数值与推荐
- 基于整个随访期的年化发生率差异,依洛尤单抗预计每 1000 例患者 5 年内可预防 31 例首次和 24 例后续 4 点 MACE,共 55 例总事件(总事件差异 95% CI:36-74)。
- 3 点 MACE 相应估计为每 1000 例患者 5 年内预防 20 例首次和 5 例后续事件,共 25 例总事件(总事件差异 95% CI:15-37)。
临床怎么用
- 对于无心肌梗死或卒中病史但存在动脉粥样硬化或高危糖尿病、LDL-C≥90 mg/dL 的患者,可考虑在优化降脂治疗基础上加用依洛尤单抗以降低总体 MACE 负担。
- 评估他汀联合依洛尤单抗的获益时,除首次事件外还应关注后续及总事件的减少。
局限性
- 总事件绝对获益的 95% CI 较宽,如 4 点 MACE 总事件差异为每 1000 例 5 年 55 例(95% CI:36-74),3 点 MACE 为 25 例(95% CI:15-37)。
- 原文摘要未报告具体不良事件数据及依洛尤单抗在该人群中的安全性细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab reduced the risk of a first major adverse cardiovascular event (MACE) in patients at high cardiovascular risk with no prior myocardial infarction (MI) or stroke in the VESALIUS-CV (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke) trial. Recurrent MACE is common and important to patients, clinicians, and health care systems. OBJECTIVES: The purpose of this study was to evaluate the effect of evolocumab on total (first and subsequent) MACE. METHODS: The VESALIUS-CV trial randomized patients with qualifying atherosclerosis or high-risk diabetes, no prior MI or stroke, and a low-density lipoprotein cholesterol ≥90 mg/dL on optimized lipid-lowering therapy to evolocumab or placebo. The dual primary endpoints were a composite of coronary heart disease death, MI, ischemic stroke, or ischemia-driven arterial revascularization (4-point [4-P] MACE) and 3-point (3-P) MACE (not including ischemia-driven arterial revascularization). In this prespecified analysis, all dual primary endpoint events (first and subsequent) were analyzed using negative binomial regression models. RESULTS: Among 12,257 patients followed for a median of 4.6 years, there were 1,654 first 4-P MACE and 1,107 subsequent events (67% more) for 2,761 total events. There were 779 first 3-P MACE and 146 subsequent events (19% more) for 925 total events. Evolocumab reduced the rate of first 4-P MACE by 19% (HR: 0.81; 95% CI: 0.73-0.89; P < 0.0001), was associated with a reduction of subsequent events by 25% (incidence rate ratio [IRR]: 0.75; 95% CI: 0.61-0.91), and reduced total events by 20% (IRR: 0.80; 95% CI: 0.71-0.90; P = 0.0002). Likewise for 3-P MACE, evolocumab reduced the rate of first events by 25% (HR: 0.75; 95% CI: 0.65-0.86; P < 0.0001), was associated with a reduction of subsequent events by 37% (IRR: 0.63; 95% CI: 0.42-0.94) and reduced total events by 27% (IRR: 0.73; 95% CI: 0.63-0.86; P = 0.0001). Based on annualized incidence rate differences over the full follow-up period, evolocumab was projected to prevent 31 first and 24 subsequent 4-P MACE, for 55 total events per 1,000 patients over 5 years (95% CI: for the total-event difference: 36-74). The corresponding estimates for 3-P MACE were 20 first and 5 subsequent events, for 25 total events per 1,000 patients over 5 years (95% CI: for the total event difference: 15-37). Results were consistent across key subgroups, including by statin intensity and presence of qualifying atherosclerosis. CONCLUSIONS: A substantial proportion of patients experiencing a cardiovascular event had more than 1 event. The addition of evolocumab reduced the total number of MACE, providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke. (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke [VESALIUS-CV]; NCT03872401).
引用
- Nicolau, Murphy, Giugliano, et al. Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study. J Am Coll Cardiol. 2026. PMID: 42663360. doi:10.1016/j.jacc.2026.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。